Work

CD38-Directed Therapies for Management of Multiple Myeloma

Year: 2021

Type: article

Abstract: The survival outcomes for multiple myeloma have improved several-fold in the past two decades, primarily due to the introduction of therapies with novel mechanisms of action including immunomodulatory agents, proteasome inhibitors, stem cell transplant and monoclonal antibodies in the schema of therapy. Antibody-based therapies targeting the surface marker CD38, namely daratumumab and isatuximab, have emerged as being highly effective as single agents as well as in combination regimens for both newly diagnosed and relapsed settings. Herein, the authors summarize the most recent data with both the current and emerging CD38-directed therapies in multiple myeloma.

Source: ImmunoTargets and Therapy

DOI: 10.2147/itt.s259122

Authors: Hamza Hashmi, Muhammad Husnain, Ali Khan, Saad Z Usmani

Institutions: Medical University of South Carolina, University of Arizona, Levine Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,320